The aim of this study is to compute the budget impact of adopting Kiovig, a new ready-to-use 10% liquid immunoglobulin preparation, as a treatment for primary immunodeficiency from the perspective of the Belgian healt...The aim of this study is to compute the budget impact of adopting Kiovig, a new ready-to-use 10% liquid immunoglobulin preparation, as a treatment for primary immunodeficiency from the perspective of the Belgian health care payer. The analysis compared the “world with Kiovig” to the “world without Kiovig” and calculated how a change in the mix of immunoglobulins used to treat primary immunodeficiency would impact drug spending during 2010-2014. Data on the number of patients, immunoglobulin market shares and drug unit costs were derived from the IMS Health hospital disease database and from Belgian sources. The number of Belgian patients suffering from primary immunodefi-ciency is expected to increase from 2,378 pa-tients in 2010 to 2,447 patients in 2014. The budget impact of adopting Kiovig is likely to be modest, raising the immunoglobulin drug bud- get for this patient population by 0.4%-1.3% per year. The budgetary increase originated from the higher price of Kiovig as compared with other products, although the impact of Kiovig was limited by its anticipated slow market penetra-tion. There is a need for more and better data on the Belgian immunoglobulin market.展开更多
为明确现阶段比利时输入中国牛精液携带施马伦贝格病毒的潜在入侵风险,基于世界动物卫生组织(Office International Des Epizooties,OIE)风险评估的框架,结合贝叶斯统计推断的方法,开展现阶段比利时拟输入中国牛精液产品携带施马伦贝格...为明确现阶段比利时输入中国牛精液携带施马伦贝格病毒的潜在入侵风险,基于世界动物卫生组织(Office International Des Epizooties,OIE)风险评估的框架,结合贝叶斯统计推断的方法,开展现阶段比利时拟输入中国牛精液产品携带施马伦贝格病毒(Schmallenberg virus,SBV)通过口岸贸易的输入量化风险评估。释放评估显示,比利时畜群存在SBV的释放风险。基于对比利时的SBV的监测监控体系、易感畜群监视、实验室诊断方法选择,结合检测方法和试剂有效性的参数化模拟,显示比利时牛精液供体动物SBV阳性预测值超过66.886 6%的概率不大于0.001 9。参照比利时2011年度出口到中国的精液批次标准,模拟现阶段比利时种用牛精液出口到中国市场每1批次中可能检出的假阴性概率在82.16%的置信区间内分布在0.001到0.006之间,即1 000批次精液的假阴性检出批次在82%的置信区间为1到6个批次,大于6个批次的假阴性概率小于13.63%,大于1个批次的概率大于95.80%。评估结论认为,从比利时输入有关的牛精液等产品将会对我国养殖畜群及其生态安全等产生较大的不确定性风险。展开更多
文摘The aim of this study is to compute the budget impact of adopting Kiovig, a new ready-to-use 10% liquid immunoglobulin preparation, as a treatment for primary immunodeficiency from the perspective of the Belgian health care payer. The analysis compared the “world with Kiovig” to the “world without Kiovig” and calculated how a change in the mix of immunoglobulins used to treat primary immunodeficiency would impact drug spending during 2010-2014. Data on the number of patients, immunoglobulin market shares and drug unit costs were derived from the IMS Health hospital disease database and from Belgian sources. The number of Belgian patients suffering from primary immunodefi-ciency is expected to increase from 2,378 pa-tients in 2010 to 2,447 patients in 2014. The budget impact of adopting Kiovig is likely to be modest, raising the immunoglobulin drug bud- get for this patient population by 0.4%-1.3% per year. The budgetary increase originated from the higher price of Kiovig as compared with other products, although the impact of Kiovig was limited by its anticipated slow market penetra-tion. There is a need for more and better data on the Belgian immunoglobulin market.
文摘为明确现阶段比利时输入中国牛精液携带施马伦贝格病毒的潜在入侵风险,基于世界动物卫生组织(Office International Des Epizooties,OIE)风险评估的框架,结合贝叶斯统计推断的方法,开展现阶段比利时拟输入中国牛精液产品携带施马伦贝格病毒(Schmallenberg virus,SBV)通过口岸贸易的输入量化风险评估。释放评估显示,比利时畜群存在SBV的释放风险。基于对比利时的SBV的监测监控体系、易感畜群监视、实验室诊断方法选择,结合检测方法和试剂有效性的参数化模拟,显示比利时牛精液供体动物SBV阳性预测值超过66.886 6%的概率不大于0.001 9。参照比利时2011年度出口到中国的精液批次标准,模拟现阶段比利时种用牛精液出口到中国市场每1批次中可能检出的假阴性概率在82.16%的置信区间内分布在0.001到0.006之间,即1 000批次精液的假阴性检出批次在82%的置信区间为1到6个批次,大于6个批次的假阴性概率小于13.63%,大于1个批次的概率大于95.80%。评估结论认为,从比利时输入有关的牛精液等产品将会对我国养殖畜群及其生态安全等产生较大的不确定性风险。
